REVIEW LEDGER
论文复核台
集中查看元数据入排不确定项,以及已识别 KM 但需确认 No. at risk 的内容复核项。
| 论文 | 元数据入排 | 图像/No. at risk 复核 | 依据 |
|---|---|---|---|
| A natural history model of oesophageal adenocarcinoma to inform power calculations for the BEST4 screening trial.PMID 42647156 · 2026-Aug-26 | needs_review未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。 | pending- | 未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。 |
| Randomized trial of adjuvant 5-FU-platinum vs paclitaxel-platinum for high-risk penile cancer.PMID 42636270 · 2026-Aug-24 | needs_review未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。 | pending- | 未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。 |
| Investigating impact of a comprehensive support program on death anxiety among women with breast cancer: a clinical trial.PMID 42618834 · 2026-Aug-20 | needs_review未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。 | pending- | 未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。 |
| Effectiveness of Theory-Based WhatsApp Chatbot Outreach in Colorectal Cancer Screening Uptake: A Randomized Controlled Trial.PMID 42617827 · 2026-Aug-19 | needs_review未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。 | pending- | 未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。 |
| Peri-procedural Lidocaine Administration for Radiofrequency Ablation of Hepatocellular Carcinoma: A Pilot Study.PMID 42617103 · 2026-Aug-18 | needs_review未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。 | pending- | 未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。 |
| Effectiveness of oral cryotherapy in preventing methotrexate-induced oral mucositis in pediatric patients with acute lymphoblastic leukemia: a randomized controlled trial.PMID 42599331 · 2026-Aug-14 | needs_review未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。 | pending- | 未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。 |
| Efficacy and Safety of Adjusting Antimicrobial Therapy in Episodes of Fever and Neutropenia Catalogued as Fever of Unknown Origin in Children with Cancer: A Randomized Clinical Trial.PMID 42650704 · 2026-Aug-13 | needs_review未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。 | pending- | 未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。 |
| Sanshimao Formula Improves Recurrence-Free Survival in Early and Intermediate Hepatocellular Carcinoma Patients with Cirrhosis: A Randomized Controlled Trial.PMID 42578431 · 2026-Aug-11 | needs_review未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。 | pending- | 未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。 |
| Soluble suppression of tumorigenicity 2 (sST2) dynamics are associated with delayed hospital discharge in patients with COVID-19: a joint-modelling analysis of the DisCoVeRy trial's longitudinal data.PMID 42567228 · 2026-Aug-07 | needs_review未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。 | pending- | 未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。 |
| Integrated narrative and cognitive therapy enhances psychological and functional recovery after ultra-low sphincter-preserving surgery for low rectal cancer: A randomized controlled trial with exploratory oncologic outcomes.PMID 42887071 · 2026-Aug-06 | needs_review未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。 | pending- | 未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。 |
| Usability and relevance of specialized population-based cancer registry data in externally controlled trials.PMID 42556756 · 2026-Aug-05 | needs_review已见 Phase III 随机试验与 time-to-event 终点,但药物干预证据不足,需复核。 | pending- | 已见 Phase III 随机试验与 time-to-event 终点,但药物干预证据不足,需复核。 |
| Feasibility of a randomised controlled trial comparing opioid dose escalation with low-dose methadone addition for refractory cancer pain: JORTC-PAL23/NCCH2309 - protocol.PMID 42551992 · 2026-Aug-04 | needs_reviewThis is a protocol for a randomized controlled trial, not a report of trial results. It does not present any formal efficacy data. The trial is randomized and drug-interventional (methadone) in an oncology setting, but it is a Phase II feasibility study (not Phase III), and it does not have a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS). The primary endpoint is feasibility (completion rate), and secondary endpoints include pain intensity and quality of life, none of which are time-to-event endpoints requiring Kaplan-Meier analysis. | pending- | This is a protocol for a randomized controlled trial, not a report of trial results. It does not present any formal efficacy data. The trial is randomized and drug-interventional (methadone) in an oncology setting, but it is a Phase II feasibility study (not Phase III), and it does not have a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS). The primary endpoint is feasibility (completion rate), and secondary endpoints include pain intensity and quality of life, none of which are time-to-event endpoints requiring Kaplan-Meier analysis. |
| Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer.PMID 42581230 · 2026-Aug | needs_review未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。 | pending- | 未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。 |
| Sequential Enzalutamide-Docetaxel Versus Abiraterone-Docetaxel Therapy in Castration-Resistant Prostate Cancer: A Subanalysis of the ENABLE Study.PMID 42598868 · 2026-Aug | needs_review未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。 | pending- | 未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。 |
| Topical Diclofenac for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Prospective Real-World Study.PMID 42623594 · 2026-Aug | needs_review未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。 | pending- | 未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。 |
| Plain language summary of subcutaneous vs IV amivantamab plus lazertinib in EGFR-altered non-small-cell lung cancer.PMID 42635093 · 2026-Aug | needs_review未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。 | pending- | 未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。 |
| Long-term results of the HD0607 trial on interim PET-adapted treatment of advanced-stage Hodgkin lymphoma beyond 10 years of follow-up.PMID 42666946 · 2026-Aug | needs_review未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。 | pending- | 未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。 |
| Plain language summary of the KRYSTAL-12 study results: adagrasib for non-small cell lung cancer with KRASG12C mutations.PMID 42745627 · 2026-Aug | needs_review未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。 | pending- | 未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。 |
| Plain language summary of the RELATIVITY-098 study results: nivolumab plus relatlimab given after melanoma is removed by surgery.PMID 42770835 · 2026-Aug | needs_review未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。 | pending- | 未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。 |
| An Evaluation of the Effect of Opioid-Free Anesthesia on Early Quality of Recovery in Patients Undergoing Gynecological Cancer Surgeries: A Randomized Controlled Trial.PMID 42701546 · 2026-Aug | needs_review未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。 | pending- | 未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。 |
| Dynamic Circulating Tumor DNA Methylation Monitoring Guiding Postoperative Surveillance in Nonmetastatic Colorectal Cancer: A Prospective, Randomized, Phase III FIND Trial.PMID 42525894 · 2026-Jul-29 | needs_reviewThe record describes a randomized, phase III, human oncology trial with primary results. However, it is excluded because (1) the intervention is a diagnostic/surveillance strategy (ctDNA-guided monitoring) without a drug-containing arm, and (2) the primary efficacy endpoint is not a time-to-event outcome but a categorical proportion of patients receiving therapy. Therefore, it does not meet the required criteria for inclusion. | pending- | The record describes a randomized, phase III, human oncology trial with primary results. However, it is excluded because (1) the intervention is a diagnostic/surveillance strategy (ctDNA-guided monitoring) without a drug-containing arm, and (2) the primary efficacy endpoint is not a time-to-event outcome but a categorical proportion of patients receiving therapy. Therefore, it does not meet the required criteria for inclusion. |
| Efficacy of alectinib for ALK-positive NSCLC according to tumor burden and body mass index: A pooled analysis of the randomized phase III trials ALEX and J-ALEX.PMID 42269244 · 2026-Jul-26 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| A multicentre phase III clinical trial of dual-epigenetic therapy plus CHOP compared with CHOP in previously untreated patients with peripheral T-cell lymphoma.PMID 42901914 · 2026-Jul-24 | needs_review已见 Phase III 和 time-to-event 信号,但随机分配证据不足,需复核。 | pending- | 已见 Phase III 和 time-to-event 信号,但随机分配证据不足,需复核。 |
| Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer.PMID 42485627 · 2026-Jul-23 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 | 未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 |
| Comparative efficacy of perioperative systemic therapies for muscle-invasive bladder cancer: a network meta-analysis of randomized trials.PMID 42485700 · 2026-Jul-22 | eligible明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 | 未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 |
| Eribulin versus taxane as first-line chemotherapy combined with dual HER2 blockade in patients with HER2-positive locally advanced or metastatic breast cancer: final survival outcomes of the JBCRG-M06/EMERALD study.PMID 42480197 · 2026-Jul-21 | eligibleThe record explicitly describes a phase III randomized trial with a drug intervention, reporting final survival outcomes (OS, PFS) as time-to-event efficacy endpoints. All required criteria are established. | needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 | 未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 |
| Systematic review and adjusted indirect comparison of first-line immune checkpoint inhibitors in metastatic colorectal cancer.PMID 42481259 · 2026-Jul-21 | eligible明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 | 未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 |
| Updated survival outcomes of SYHX2011 versus albumin-bound paclitaxel in advanced breast cancer: A randomized double-blind phase III trial.PMID 42483812 · 2026-Jul-21 | eligible明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 | 未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 |
| The Role of Locoregional Treatment in Non-Progressive De Novo Metastatic Breast Cancer under Systemic Treatment: A Randomized Controlled Trial (LTMBC).PMID 42472751 · 2026-Jul-20 | eligibleOriginal Phase III randomized trial evaluating locoregional treatment versus systemic therapy in de novo metastatic breast cancer, with primary OS endpoint. The study is drug-containing (systemic therapy is the comparator and maintenance treatment). | needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 | 未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 |
| TANGENT study design: a phase III, randomized study of emactuzumab for the treatment of tenosynovial giant cell tumors.PMID 42473802 · 2026-Jul-20 | needs_reviewThis is a protocol design paper for a Phase III randomized trial, not a report of formal results. The abstract describes the study rationale and design but does not present any efficacy data, including time-to-event endpoints such as OS, PFS, DFS, or associated Kaplan-Meier estimates or hazard ratios. | pending- | This is a protocol design paper for a Phase III randomized trial, not a report of formal results. The abstract describes the study rationale and design but does not present any efficacy data, including time-to-event endpoints such as OS, PFS, DFS, or associated Kaplan-Meier estimates or hazard ratios. |
| Design-Outcome Concordance in Targeted-Therapy trials in Non-Small cell lung cancer: a Meta-Research study.PMID 42477876 · 2026-Jul-20 | eligible明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | needs_review未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 | 未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。 |
| Ensartinib in Resected ALK-Positive Non-Small-Cell Lung Cancer.PMID 42418775 · 2026-Jul-09 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Efficacy and safety of eribulin mesylate vs. docetaxel or paclitaxel, combined with trastuzumab and pertuzumab, as first-line treatment for HER2-positive locally advanced or metastatic breast cancer: updated subgroup analyses of JBCRG-M06/EMERALD.PMID 42420599 · 2026-Jul-08 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Randomized phase III trial of gemcitabine plus nab-paclitaxel versus gemcitabine plus S-1 as neoadjuvant chemotherapy for resectable pancreatic cancer in geriatric patients: JCOG2101C (PRESTIGE study).PMID 41968990 · 2026-Jul-06 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Orelabrutinib versus chemoimmunotherapy in treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma: a randomized, phase 3 trial.PMID 42402625 · 2026-Jul-06 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 | 历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 |
| Omission of axillary lymph node dissection in ultrasound-detectable axillary metastases in primary breast cancer treated by upfront surgery: prospective randomized SENOMAC-ULTRA non-inferiority trial.PMID 42551036 · 2026-Jul-03 | needs_review未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。 | pending- | 未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。 |
| Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma.PMID 42384869 · 2026-Jul-02 | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Direct oral anticoagulants in cancer-associated venous thromboembolism: trial robustness and clinical trade-offs.PMID 42620909 · 2026-Jul | needs_review未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。 | pending- | 未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。 |
| Long-Term Dietary Changes and Mortality among Participants of a Whole Food Plant-Based Pilot Study for Metastatic Breast Cancer.PMID 42473551 · 2026-Jul | needs_reviewThe record describes a long-term follow-up of a small pilot feasibility study of a dietary (whole food plant-based) intervention in metastatic breast cancer. It is a randomized study, but it is not a definitive Phase II/III or Phase III/IIIb trial, the intervention is non-drug, and the primary reported outcomes are mortality counts (not a formal time-to-event analysis with KM or HR) and dietary adherence, which is not an efficacy endpoint. Therefore, it does not meet the eligibility criteria. | pending- | The record describes a long-term follow-up of a small pilot feasibility study of a dietary (whole food plant-based) intervention in metastatic breast cancer. It is a randomized study, but it is not a definitive Phase II/III or Phase III/IIIb trial, the intervention is non-drug, and the primary reported outcomes are mortality counts (not a formal time-to-event analysis with KM or HR) and dietary adherence, which is not an efficacy endpoint. Therefore, it does not meet the eligibility criteria. |
| Temporal variability in outcomes of identical regimens across newly diagnosed myeloma trials: a systematic review.PMID 42473535 · 2026-Jul | needs_reviewEligibility is uncertain because the record is a systematic review of multiple trials, not an original result report of a single randomized trial. While it involves oncology, human subjects, randomized trials, and a time-to-event endpoint, it does not meet the 'original_result' criterion. Drug intervention is not clearly the focus of an original trial report here. | pending- | Eligibility is uncertain because the record is a systematic review of multiple trials, not an original result report of a single randomized trial. While it involves oncology, human subjects, randomized trials, and a time-to-event endpoint, it does not meet the 'original_result' criterion. Drug intervention is not clearly the focus of an original trial report here. |
| Final overall survival analysis and exploratory biomarker study from JUPITER-06: a randomized phase III trial of toripalimab plus chemotherapy in advanced esophageal squamous-cell carcinoma.PMID 41571044 · 2026-Jul | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| OPTIMAL: a multinational phase III study of oral paclitaxel (DHP107) versus intravenous weekly paclitaxel in HER2-negative recurrent or metastatic breast cancer.PMID 41833903 · 2026-Jul | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Comparing paclitaxel and platinum-based concurrent chemoradiotherapy with short-term adjuvant chemotherapy versus platinum-based monotherapy concurrent chemoradiotherapy in patients with postoperative gastric-type endocervical adenocarcinoma with high-risk factors for recurrence: a multicenter randomized phase III trial.PMID 41834413 · 2026-Jul | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Clinical and molecular biomarkers for prediction of endocrine response after short preoperative endocrine therapy in the WSG ADAPT-HR+/HER2- and ADAPTcycle trials (N = 7914).PMID 41999978 · 2026-Jul | eligible明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| IO102-IO103 immune-modulatory cancer vaccine and pembrolizumab in melanoma.PMID 42025759 · 2026-Jul | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| First-line pembrolizumab plus chemotherapy versus chemotherapy alone for advanced esophageal cancer: 5-year extended follow-up in the Japanese subgroup of KEYNOTE-590.PMID 42047965 · 2026-Jul | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 | 历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。 |
| Final overall survival analysis of the APPLE study: atezolizumab and platinum-pemetrexed with or without bevacizumab for metastatic nonsquamous non-small cell lung cancer.PMID 42127535 · 2026-Jul | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Bladder Adjuvant Radiotherapy: Phase III Multicenter Randomized Controlled Trial of Adjuvant Radiotherapy or Observation for Postcystectomy Muscle-Invasive Bladder Cancer.PMID 42166701 · 2026-Jul | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Lenvatinib plus pembrolizumab in participants with advanced or recurrent endometrial cancer: Study 309/KEYNOTE-775 and ENGOT-en9/LEAP-001 post-(neo)adjuvant therapy outcomes.PMID 42167105 · 2026-Jul | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |
| Adjuvant chemoradiotherapy versus completion total mesorectal excision after local excision for early rectal cancer (TESAR): a multicentre, randomised, controlled, phase 3, non-inferiority trial.PMID 42202843 · 2026-Jul | eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 | 历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。 |